XMU-MP-1 NEW
| Price | $48 | $72 | $98 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: XMU-MP-1 | CAS No.: 2061980-01-4 |
| Purity: 99.68% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | XMU-MP-1 |
| Description | XMU-MP-1 is an inhibitor of the pro-apoptotic, sterile 20-like kinases MST1 and 2. |
| Kinase Assay | XMU-MP-1 is dissolved in DMSO (stock concentration, 10 mM). For the in vitro kinase inhibition assays, recombinant GST-tagged MOB1a and various forms of recombinant His-tagged full-length MST1 or MST2 kinase are expressed and purified from Escherichia coli. The assays are performed with the various doses of XMU-MP-1 in the kinase assay buffer for 30 min at 30°C[1]. |
| In vitro | XMU-MP-1 effectively reduces the phosphorylation of MOB1, LATS1/2, and YAP in HepG2 cells in a concentration-dependent manner, with effective doses ranging from 0.1 to 10 μM. It also inhibits MOB1 phosphorylation induced by hydrogen peroxide and prevents MST1/2 autophosphorylation across various cell lines, including mouse macrophage-like cells, human osteosarcoma, and human colorectal adenocarcinoma cells. By blocking MST1/2 kinase activities, XMU-MP-1 activates the downstream effector, Yes-associated protein (YAP), thereby promoting cell growth. Its action potently and reversibly suppresses the activities of MST1/2 kinases, enhancing YAP activation in cells. |
| In vivo | XMU-MP-1 demonstrates excellent in vivo pharmacokinetics and enhances intestinal repair, as well as liver repair and regeneration, in both acute and chronic liver injury mouse models at doses of 1 to 3 mg/kg via intraperitoneal injection. In the Fah-deficient mouse model, XMU-MP-1 treatment significantly increased the repopulation rate of human hepatocytes compared to the vehicle-treated control, suggesting it may facilitate human liver regeneration. Therefore, pharmacological modulation of [MST1/2] kinase activities offers a novel method to enhance tissue repair and regeneration, with XMU-MP-1 as the initial lead for developing targeted regenerative therapeutics. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 12.5 mg/mL (30.01 mM) |
| Keywords | XMU MP 1 | Inhibitor | Hippo (MST) | inhibit | XMUMP1 | XMU-MP-1 |
| Inhibitors Related | Pim1/AKK1-IN-1 | I3MT-3 | IHMT-MST1-58 | Cerdulatinib hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Stem Cell Differentiation Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
![[11C]MP 10](https://img.chemicalbook.com/ProductImageEN1/2024-11/Large/53794ffa-885c-4e40-b39e-811315ead6cd.png)
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/100mg |
VIP1Y
|
Xian confluore Biological Technology Co., Ltd.
|
2024-04-01 | |
| $4570.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY